Drug discontinuation: Fosaprepitant Dimeglumine Injection (FOSAPREPITANT)
FDA lists 1 presentation as To Be Discontinued. Companies: Fresenius Kabi USA, LLC.
- Published by source
- 2026-04-08
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Fresenius Kabi USA, LLC
- Products
- Fosaprepitant Dimeglumine Injection FOSAPREPITANT
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Discontinuation of the manufacture of the drug
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-04-08
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1056 | new | 2026-10-22 | 96725667112c…11e9d7 | 9ab54b285c3f…2afb10 |
Chain head: #1076 8ad5adc30b9b…88ce20